NasdaqGS - Delayed Quote USD

Kamada Ltd. (KMDA)

5.20 +0.02 (+0.39%)
At close: April 25 at 4:00 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for KMDA

Recent News: KMDA

View More
KMDA: Double Digit Growth Anticipated in 2024 with $158 Million in Expected Revenues and $28 Million in Expected Adjusted EBITDA…

KMDA: Double Digit Growth Anticipated in 2024 with $158 Million in Expected Revenues and $28 Million in Expected Adjusted EBITDA…
Zacks Small Cap Research last month
Kamada Ltd. (NASDAQ:KMDA) Q4 2023 Earnings Call Transcript

Kamada Ltd. (NASDAQ:KMDA) Q4 2023 Earnings Call Transcript
Insider Monkey last month
Kamada Issues 2024 CEO Letter to Shareholders

Kamada Issues 2024 CEO Letter to Shareholders
GlobeNewswire last month
Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability

Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability
GlobeNewswire last month
Kamada to Announce Fourth Quarter and Fiscal Year 2023 Financial Results, and Provide 2024 Financial Guidance on March 6, 2024

Kamada to Announce Fourth Quarter and Fiscal Year 2023 Financial Results, and Provide 2024 Financial Guidance on March 6, 2024
GlobeNewswire last month
KEDRION ANNOUNCES AN EIGHT-YEAR EXTENSION OF THE DISTRIBUTION AGREEMENT WITH KAMADA IN THE US FOR KEDRAB®

KEDRION ANNOUNCES AN EIGHT-YEAR EXTENSION OF THE DISTRIBUTION AGREEMENT WITH KAMADA IN THE US FOR KEDRAB®
PR Newswire 4 months ago

KMDA: Amendment and Extension of Kedrab® U.S. Distribution Agreement to Generate at Least $180 Million Over First Four Years…
Zacks Small Cap Research 4 months ago
Kamada Announces its Largest Commercial Agreement; A Strategic Engagement with Kedrion for U.S. Distribution of KEDRAB® including $180 Million of Revenues Over First Four Years

Kamada Announces its Largest Commercial Agreement; A Strategic Engagement with Kedrion for U.S. Distribution of KEDRAB® including $180 Million of Revenues Over First Four Years
GlobeNewswire 4 months ago
KMDA: $37.9 Million in 3Q23 Revenues; Closes $60 Million Private Placement with FIMI Opportunity Funds…

KMDA: $37.9 Million in 3Q23 Revenues; Closes $60 Million Private Placement with FIMI Opportunity Funds…
Zacks Small Cap Research 5 months ago
Kamada Reports Significant Increase in Sales and Profitability in the Third Quarter and Nine Month 2023; Reiterates 2023 Revenue and Profitability Guidance

Kamada Reports Significant Increase in Sales and Profitability in the Third Quarter and Nine Month 2023; Reiterates 2023 Revenue and Profitability Guidance
GlobeNewswire 5 months ago
Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023

Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023
GlobeNewswire 5 months ago
Kamada Announces Recent Achievements with CYTOGAM® including Availability of Product Manufactured by the Company for U.S Commercial Sale and Presentation of New Clinical Data

Kamada Announces Recent Achievements with CYTOGAM® including Availability of Product Manufactured by the Company for U.S Commercial Sale and Presentation of New Clinical Data
GlobeNewswire 6 months ago
View More

Related Tickers

TARO Taro Pharmaceutical Industries Ltd.
42.48
+0.66%
 
LFCR Lifecore Biomedical, Inc.
6.64
+4.90%
 
PBH Prestige Consumer Healthcare Inc.
70.14
+0.01%
 
INCR InterCure Ltd.
2.6400
-1.12%
 
INDV Indivior PLC
17.25
-8.29%
 
PETQ PetIQ, Inc.
16.32
-1.27%
 
EVO Evotec SE
5.10
-2.49%
 
AMRX Amneal Pharmaceuticals, Inc.
5.90
-2.48%
 
RDHL RedHill Biopharma Ltd.
0.4162
-0.88%
 
FAGI Full Alliance Group, Inc.
0.0116
0.00%